Bullboard - Stock Discussion Forum Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up... see more

Add To Watchlist

GREY:COTQF - Post Discussion

Cotinga Pharmaceuticals Inc > Significant change of protocol from FDA

View:

Post by jcjohn36 on May 29, 2018 3:57pm

Significant change of protocol from FDA

Not sure what to make of this news?

https://globenewswire.com/news-release/2018/05/24/1511485/0/en/Cotinga-Pharmaceuticals-Announces-FDA-Clearance-of-Significant-Protocol-Changes-for-COTI-2-Clinical-Program.html

Anyone with more knowledge? I would have thought that they would have hoped that COTI would have been a success on its own rather than as a combination therapy.

Nice to see the stock get a boost.

Best,
JC

180